Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.48 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.37 |
| ▸ | KDM4A | O75164 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.37 |
| ▸ | TET3 | O43151 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10197452 | 0.81 | OR51E2 (0.39) | BCAT2OR51E2SMN1; SMN2TET2KDM4A | |
| SCHEMBL29222634 | 0.79 | BCAT2 (0.47) | BCAT2MEN1KMT2ATDP1CYP2D6 | |
| SCHEMBL18125949 | 0.79 | CYP2D6 (0.52) | OR51E2SMN1; SMN2TET2KDM4AKDM4C | |
| SCHEMBL538750 | 0.76 | — | — | |
| SCHEMBL12461756 | 0.76 | BCAT2 (0.48) | BCAT2MEN1KMT2ATDP1CYP2D6 | |
| Albizziine SCHEMBL1006299 | 0.75 | GFPT1 (0.48) | BCAT2KMT2A | |
| Albizziine SCHEMBL690347 | 0.75 | GFPT1 (0.48) | BCAT2KMT2A | |
| Albizziine SCHEMBL9361011 | 0.75 | GFPT1 (0.48) | BCAT2KMT2A | |
| Albizziine SCHEMBL1006298 | 0.75 | GFPT1 (0.48) | BCAT2KMT2A | |
| Albizziine SCHEMBL439790 | 0.75 | GFPT1 (0.48) | BCAT2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080118453-A1 | Film-forming solutions comprising vitamin D or derivative thereof and a corticosteroid and dermatological applications thereof | GALDERMA S.A. (CH) | 2008-05-22 | — | — | US | claimed |
| EP-1874320-A1 | COMPOSITION OF FILM-FORMING SOLUTION TYPE, COMPRISING VITAMIN D OR A DERIVATIVE THEREOF AND A CORTICOSTEROID, AND USE THEREOF IN DERMATOLOGY | Galderma S.A. (CH) | 2008-01-09 | — | — | EP | claimed |
| WO-2006111426-A1 | COMPOSITION OF FILM-FORMING SOLUTION TYPE, COMPRISING VITAMIN D OR A DERIVATIVE THEREOF AND A CORTICOSTEROID, AND USE THEREOF IN DERMATOLOGY | GALDERMA S.A. (CH) | 2006-10-26 | — | — | WO | claimed |
| US-20230374330-A1 | CONDUCTIVE ELECTRONIC TEXTILES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-11-23 | — | — | US | disclosed |
| US-20220257545-A1 | pH STABLE UREA COMPOSITION AND USE THEREOF | Orenova Development Company LLC | 2022-08-18 | — | — | US | disclosed |
| US-20200085764-A1 | TOPICAL DELIVERY OF NUCLEIC ACID COMPOUNDS | PHIO PHARMACEUTICALS CORP. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3612152-A1 | TOPICAL DELIVERY OF NUCLEIC ACID COMPOUNDS | Phio Pharmaceuticals Corp. (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018195355-A1 | TOPICAL DELIVERY OF NUCLEIC ACID COMPOUNDS | RXI PHARMACEUTICALS CORPORATION (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20110218506-A1 | AMOROLFINE PATCH FOR THE TREATMENT OF ONYCHOMYCOSIS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-09-08 | — | — | US | disclosed |
| US-20100291012-A1 | ADMINISTRATION OF AMOROLFINE BY IONTOPHORESIS FOR TREATING NAIL DISEASES | GALDERMA S.A. (CH) | 2010-11-18 | — | — | US | disclosed |
| EP-2222307-A1 | USE OF AMOROLFINE FOR TREATING A NAIL DISEASE BY IONTOPHORESIS | Galderma S.A. (CH) | 2010-09-01 | — | — | EP | disclosed |
| CN-1222923-A | Spray-dried polymer compositions and methods thereof | CYTEC TECH CORP (US) | 1999-07-14 | — | — | CN | disclosed |
| EP-0906359-A1 | SPRAY-DRYING OIL RECOVERY PROCESS | Cytec Technology Corp. (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0906364-A1 | WATER-IN-OIL EMULSION SPRAY DRYING PROCESS | Cytec Technology Corp. (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0906358-A2 | SPRAY-DRIED POLYMER COMPOSITIONS AND METHODS | Cytec Technology Corp. (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5869542-A | CONDENSING TO OBTAIN CONDENSED OIL AND CONDENSED WATER; SEPARATION; CONDENSED OIL IS SUBSTANTIALLY FREE OF NON-GASEOUS POLYMERIZATION-DEBILITATING SUBSTANCES; UTILIZES AQUEOUS ACID | CYTEC TECHNOLOGY CORP. (US) | 1999-02-09 | — | — | US | disclosed |
| US-5849862-A | Processes of spray drying polymer-containing dispersions, water-in-oil emulsions and water-in-oil microemulsions | CYTEC TECHNOLOGY CORP. (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1997048755-A1 | WATER-IN-OIL EMULSION SPRAY DRYING PROCESS | CYTEC TECHNOLOGY CORP. (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997048750-A1 | SPRAY-DRYING OIL RECOVERY PROCESS | CYTEC TECHNOLOGY CORP. (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997048732-A2 | SPRAY-DRIED POLYMER COMPOSITIONS AND METHODS | CYTEC TECHNOLOGY CORP. (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200085764-A1 | TOPICAL DELIVERY OF NUCLEIC ACID COMPOUNDS | SNRPE, MTREX, NSUN2 | BCAT2 4669/4885OR51E2 2378/4885SMN1; SMN2 914/4885 |
| US-20110218506-A1 | AMOROLFINE PATCH FOR THE TREATMENT OF ONYCHOMYCOSIS | ETF1, SLC7A1, SLC16A1 | BCAT2 267/4885OR51E2 232/4885SMN1; SMN2 4847/4885 |
| US-20100291012-A1 | ADMINISTRATION OF AMOROLFINE BY IONTOPHORESIS FOR TREATING NAIL DISEASES | ETF1, SLC7A1, DPM1 | BCAT2 1432/4885OR51E2 1539/4885SMN1; SMN2 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.